Christopher Ryan Sullivan, Chief Financial Officer at Avalo Therapeutics, sold AVTX on Sep 16, 2026
Prices as of Oct 16 · price update delayed · Every feed →
▼ SELL$202K12,394 shares at $16.33Christopher Ryan Sullivan Chief Financial OfficerAVTX Avalo Therapeutics, Inc.
- Traded
- Sep 16, 2026
- Disclosed
- Sep 18, 2026
- Filed
- 2 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
AVTX since disclosure
−32.0%
after the sale
Similar stocks (XLV) since disclosure
+4.9%
XLV — its sector index fund
Change in closing price from Sep 18, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.